Negative Meta-cognitions as a Causal Factor to Worry

Negative Meta-cognitions as a Causal Factor to Worry: A Randomized Controlled Trial

The purpose of this study is to investigate if an internet-based metacognitive therapy reduces negative metacognitions and if reductions negative metacognitions mediates reductions in worry.

Study Overview

• Status: Completed
• Conditions: Excessive Worry
• Intervention / Treatment: Behavioral: Internet-based metacognitive therapy

Detailed Description

The aim is primary mechanistic i.e. we want to investigate if a clear change in negative metacognitions in one group (internet-based metacognitive therapy; I-MCT) relative to another (waiting list) mediates subsequent reductions in worry.

Our hypotheses are the following:

1. I-MCT reduces both negative metacognitions (Beliefs about uncontrollability and danger of worry) and worry from baseline to week 10,

2. reductions in negative metacognitions will significantly mediate subsequent reductions in worry.

   Additionally we hypothesize that patients who score low at baseline in negative metacognitions will not show this process pattern i.e.

3. patients who score low at baseline in negative metacognitions will benefit less from treatment (moderator hypothesis)

   and consequently

4. will not show the same mediation response as stipulated in hypothesis 2 (moderated mediator hypothesis).

Trial Design: Randomized controlled trial with waitlist control. Duration: Ten weeks Primary Endpoint: Change in worry symptoms and negative metacognitions from baseline to Week 10. Long term follow-up is also investigated (baseline to 6-months after treatment completion and baseline to 12-months after treatment completion).

Efficacy Parameters: Penn State Worry Questionnaire (PSWQ) and the negative metacognitions subscale (negative beliefs about uncontrollability of thoughts and danger) of the Meta-Cognitions Questionnaire 30 items.

Safety Parameters: Adverse Events is assessed at week 10.

Description of Trial Subjects: Patients > 18 years old with a PSWQ score more than 56 points Number of Subjects: Anticipated 140

Analysis plan:

To address the hypotheses in the study growth modeling analysis using the expectation-maximization algorithm and maximum-likelihood estimation will be employed. The treatment effect on negative metacognitions and worry will examined by comparing average growth rates between treatment and control group over the assessment period. Growth modeling for longitudinal mediation will be employed to test (a) the overall mediated effect on worry using individual trajectories of change on the proposed mediator (i.e., negative metacognitions) and outcome (i.e., worry), and (b) mediated baseline by treatment moderation effect using the initial assessment of negative metacognitions as the moderator of the indirect (i.e., mediated) and direct effect of treatment. Competing mediator is depressive symptoms using the PHQ-2.

• Study Type: Interventional
• Enrollment (Actual): 108
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Sweden
  • Stockholm, Sweden, 17177
    • Karolinska Intitutet

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Outpatients
• ≥ 18 years
• Situated in Sweden
• Informed consent
• PSWQ score more than 56 points

Exclusion Criteria:

• Substance dependence during the last six months
• Post traumatic stress disorder, bipolar disorder or psychosis
• Symptoms better explained by axis 2 diagnosis (e.g. autism or borderline personality disorder)
• MADRS-S score above 25 points
• Psychotropic medication changes within two months prior to treatment that could affect target symptoms.
• Received metacognitive therapy for pathological worry the last 2 years.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Internet-based metracognitive therapy; The internet-based metacognitive therapy group receives a ten-week long treatment, which is based on the book "Metacognitive therapy for depression and anxiety" by Adrian Wells (2011).	Behavioral: Internet-based metacognitive therapy; Internet-based metacognitive therapy on a safe internet platform. Treatment is divided into ten modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hour
NO_INTERVENTION: Wait-list; When the active treatment groups have finished treatment (W11), the WL group will be able to start active treatment and be assessed at post-treatment, 6 and 12 months later using the same questionnaires as the treatment group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Penn State Worry Questionnaire (PSWQ)	Change in worry, weekly measurements, and at 6 and 12 months after treatment has ended.	Weekly measurements week 0-10, 6 and 12 months follow-up
Negative beliefs about uncontrollability of thoughts and danger in the Meta Cognitions Questionnaire (MCQ-30)	Change in Negative beliefs about uncontrollability of thoughts and danger, weekly measurements, and at 6 and 12 months after treatment has ended.	Weekly measurements week 0-10, 6 and 12 months follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Montgomery Åsberg Depression Rating Scale (MADRS-S)	Change in depression from baseline to Week 10 and at 6 and 12 months after treatment has ended.	Week 0, Week 10, 6 and 12 months follow-up
Euroqol, EQ-5D	Change in general health from baseline to Week 10 and at 6 and 12 months after treatment has ended	Week 0, Week 10, 6 and 12 months follow-up
Trimbos and Institute of Medical Technology Assessment Cost Questionnaire for Psychiatry (TIC-P) [Time Frame: Week 0, Week 10, 6 and 12 months follow-up]	Change in economic costs from baseline to Week 10 and at 6 and 12 months after treatment has ended	Week 0, Week 10, 6 and 12 months follow-up
Meta Cognitions Questionnaire (MCQ-30)	Change in metacognitions (all subscales as a total sum) weekly and at 6- and 12 months after treatment has ended.	Weekly measurements, 6 and 12 months follow-up
Cognitive Avoidance Questionnaire (CAQ)	Change in cognitive avoidance from baseline to Week 10 and at 6- and 12 months after treatment has ended	Week 0, Week 10, 6 and 12 months follow-up
Adverse Events	Number of adverse events from baseline to Week 10 and at 6 and 12 months	Week 10, 6 and 12 months follow-up
Contrast avoidance questionnaire	Change in contrast avoidance from baseline to Week 10 and at 6- and 12 months after treatment has ended	Week 0, Week 10, 6 and 12 months follow-up
Patient health questionnaire 2 items (PHQ-2)	Change in depressive symptoms weekly measurements, and at 6 and 12 months after treatment has ended.	Week 0 - Week 10 (weekly measurements), 6 and 12 months follow-up

Collaborators and Investigators

• Sponsor: Karolinska Institutet
• Investigators: Principal Investigator: Erik M Andersson, PhD, Psych., Karolinska Institutet

Publications and helpful links

General Publications

• Wahlund T, Hesser H, Perrin S, Johansson S, Huhn V, Sorhus S, Lindskog S, Serlachius E, Hedman-Lagerlof E, Ljotsson B, Andersson E. Therapist-guided online metacognitive intervention for excessive worry: a randomized controlled trial with mediation analysis. Cogn Behav Ther. 2022 Jan;51(1):21-41. doi: 10.1080/16506073.2021.1937695. Epub 2021 Jul 20.

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 6, 2018
• Primary Completion (ACTUAL): May 6, 2018
• Study Completion (ACTUAL): May 6, 2018

Study Registration Dates

• First Submitted: January 2, 2018
• First Submitted That Met QC Criteria: January 2, 2018
• First Posted (ACTUAL): January 8, 2018

Study Record Updates

• Last Update Posted (ACTUAL): August 7, 2018
• Last Update Submitted That Met QC Criteria: August 6, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Other Study ID Numbers: 2017/1998-31

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No